Hoppa till huvudinnehåll
For Healthcare
Professionals
Products
Tools
Therapeutic areas
Contact
Svenska
Products
ALTUVOCT®
Doptelet
Kineret
Tools
Therapeutic areas
Haematology
Immunology
Contact
Normalised Haemostasis
Active ingredients and Molecule
Trough levels and half-life
XTEND-1 Study
XTEND-kids Study
Dosing
Vial sizes
Treating Bleeds
Perioperative Management
Altuvoct Safety Profile
Scientific resources
Prescribing information
ALTUVOCT
®
Moves Towards Sustained Normalisation of Haemostasis in a Physiological Way
1-3,*
XTEND-1 Study Design
1
References
von Drygalski A et al. N Engl J Med 2023;388:310–8
Malec L et al. N Engl J Med 2024;391:235–46 ;
Srivastava A et al. Haemophilia 2020;26:1–158;
Lissitchkov T et al. Res Pract Thromb Haemost 2023;7:100176;
PP-34699
Products
ALTUVOCT®
Normalised Haemostasis
Active ingredients and Molecule
Trough levels and half-life
XTEND-1 Study
XTEND-kids Study
Dosing
Vial sizes
Treating Bleeds
Perioperative Management
Altuvoct Safety Profile
Scientific resources
Prescribing information
Doptelet
Introduction to ITP
About ITP
Challenge expectations in ITP
Today’s expectations
Challenge expectations
Efficacy
Durable response within 8 days
Consistent response
Effect and durable response
Dosing
Safety profile
Guidelines
Prescribing information
Kineret
This is how Kineret works
Resources
Prescribing information
Tools
Therapeutic areas
Haematology
Immune thrombocytopenia (ITP)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Immunology
Contact
Logga in
Other sites
expand_less